Gallagher Capital Advisors LLC Grows Position in Eli Lilly and Company $LLY

Key Points

• Gallagher Capital Advisors LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 326.4%, owning 1,744 shares worth approximately $1.35 million after acquiring an additional 1,335 shares in Q2.
• Eli Lilly's quarterly earnings revealed an EPS of $6.31, surpassing analyst expectations of $5.59, with revenue at $15.56 billion, a year-over-year increase of 37.6%.
• Analysts maintain a consensus rating of "Moderate Buy" for Eli Lilly shares, with a target price averaging $938.61 despite mixed ratings from different firms.

Gallagher Capital Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 326.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,744 shares of the company's stock after buying an additional 1,335 shares during the quarter. Gallagher Capital Advisors LLC's holdings in Eli Lilly and Company were worth $1,349,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Hoge Financial Services LLC grew its stake in shares of Eli Lilly and Company by 3.7% in the second quarter. Hoge Financial Services LLC now owns 454 shares of the company's stock worth $353,000 after acquiring an additional 16 shares during the period. KPP Advisory Services LLC grew its position in Eli Lilly and Company by 11.6% in the 2nd quarter. KPP Advisory Services LLC now owns 3,535 shares of the company's stock worth $2,756,000 after purchasing an additional 368 shares during the period. First Citizens Bank & Trust Co. raised its stake in Eli Lilly and Company by 13.0% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 15,513 shares of the company's stock valued at $12,093,000 after buying an additional 1,782 shares during the last quarter. Roman Butler Fullerton & Co. boosted its stake in shares of Eli Lilly and Company by 2.9% in the 2nd quarter. Roman Butler Fullerton & Co. now owns 8,973 shares of the company's stock worth $7,293,000 after buying an additional 249 shares during the last quarter. Finally, Cornerstone Advisory LLC increased its position in Eli Lilly and Company by 0.6% during the second quarter. Cornerstone Advisory LLC now owns 2,591 shares of the company's stock valued at $2,020,000 after acquiring an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $819.72 on Thursday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm's fifty day moving average is $762.81 and its two-hundred day moving average is $766.75. The company has a market cap of $775.83 billion, a P/E ratio of 53.41, a P/E/G ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LLY shares. Guggenheim reiterated a "buy" rating and issued a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. JPMorgan Chase & Co. reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. Finally, The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $938.61.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jamere Jackson bought 200 shares of the company's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.